Syntenin gain-of-function was first described in metastatic melanoma (Helmke et al., 2004), and more recently in breast cancer (Qian et al., 2013; Yang et al., 2013) and in multiple neuroepithelial tumors (Kegelman et al., 2014) suggesting that syntenin could be a tumor marker. Here, SDCBP is linked to breast carcinoma.